Changeflow GovPing Pharma & Drug Safety Anti-Lea Reagent Safety Alert - Diagast Immuno-...
Priority review Notice Added Final

Anti-Lea Reagent Safety Alert - Diagast Immuno-Hematology

Favicon for ansm.sante.fr ANSM Drug & Device Safety Alerts
Published
Detected
Email

Summary

ANSM issued safety alert R2610123 regarding a security action taken by Diagast for its Anti-Lea Reagent (LE1) used in immuno-hematology testing. Medical biology laboratories using this diagnostic reagent must review the manufacturer's safety communication and take appropriate action. ANSM reference number R2610123.

What changed

ANSM issued safety alert R2610123 notifying medical biology laboratories of a security action performed by Diagast for its Anti-Lea Reagent (LE1) used in immuno-hematology testing. The alert references a manufacturer communication dated 10/04/2026 that users have received directly.

Medical laboratories using Diagast immuno-hematology reagents must review the manufacturer's safety communication, verify whether they hold affected products, and implement any required corrective actions. This alert represents a substantive safety action affecting diagnostic testing procedures in clinical laboratory settings.

What to do next

  1. Review the Diagast manufacturer communication for Anti-Lea Reagent safety action
  2. Identify and quarantine any affected Diagast Anti-Lea Reagent products in your laboratory
  3. Report any adverse incidents related to the reagent to ANSM

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

A+ A-

Information n° R2610123 destinée aux laboratoires d'analyses de biologie médicale L'ANSM a été informée de la mise en œuvre d’une action de sécurité effectuée par la société Diagast.

Les utilisateurs concernés ont reçu le courrier ci-joint.

Cette action de sécurité est enregistrée à l’ANSM sous le n° R2610123. Pour toute question, merci de vous adresser directement à l’émetteur de l’action de sécurité. Téléchargez le courrier de la société Diagast (10/04/2026)

Named provisions

Anti-Lea Reagent (LE1) Diagast

Get daily alerts for ANSM Drug & Device Safety Alerts

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from ANSM.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
ANSM
Published
April 10th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Substantive
Document ID
R2610123
Docket
R2610123

Who this affects

Applies to
Healthcare providers
Industry sector
3345 Medical Device Manufacturing
Activity scope
Immuno-hematology testing Diagnostic reagent handling
Geographic scope
France FR

Taxonomy

Primary area
Medical Devices
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Healthcare Public Health

Get alerts for this source

We'll email you when ANSM Drug & Device Safety Alerts publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!